Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML.

[1]  Ashutosh Kumar Singh,et al.  Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. , 2023, Clinical lymphoma, myeloma & leukemia.

[2]  Wenxiu Yang,et al.  TKIs combined with chemotherapy followed by allo-HSCT in Philadelphia chromosome-positive myelodysplastic syndrome: A case report and literature review , 2022, Medicine.

[3]  Zilin Li,et al.  The Activity of Novel BCR-ABL Small-Molecule Degraders Containing Pyrimidine Rings and Their Role in Overcoming Drug Resistance , 2022, Journal of oncology.

[4]  Xiaobao Yang,et al.  Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor. , 2022, European journal of medicinal chemistry.

[5]  M. Oba,et al.  Recent Advances in PROTAC Technology Toward New Therapeutic Modalities , 2022, Chemistry & biodiversity.

[6]  Jiaojiao Zhao,et al.  Recent Advances of Degradation Technologies Based on PROTAC Mechanism , 2022, Biomolecules.

[7]  You-lu Pan,et al.  The progress of small-molecules and degraders against BCR-ABL for the treatment of CML. , 2022, European journal of medicinal chemistry.

[8]  Dajun Yang,et al.  Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review. , 2022, Journal of comparative effectiveness research.

[9]  R. Nussinov,et al.  Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs. , 2022, Journal of molecular biology.

[10]  Chao Wang,et al.  The state of the art of PROTAC technologies for drug discovery. , 2022, European journal of medicinal chemistry.

[11]  M. IJzerman,et al.  Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review , 2022, European journal of haematology.

[12]  D. Langley,et al.  PROTAC targeted protein degraders: the past is prologue , 2022, Nature Reviews Drug Discovery.

[13]  N. Charoenngam,et al.  Effects of different types of allogeneic hematopoietic stem cell transplantation donors on Philadelphia chromosome-positive acute lymphoblastic leukemia during the tyrosine kinase inhibitor era: A systematic review and meta-analysis. , 2021, Hematology/oncology and stem cell therapy.

[14]  Xiaoju Wang,et al.  Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression. , 2021, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[15]  Qifeng Yang,et al.  Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28 , 2021, Theranostics.

[16]  Zhimin Zhang,et al.  Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. , 2020, European journal of medicinal chemistry.

[17]  Li‐Ping Sun,et al.  PROTAC: A promising technology for cancer treatment. , 2020, European journal of medicinal chemistry.

[18]  Xiuyun Sun,et al.  PROTACs: great opportunities for academia and industry , 2019, Signal Transduction and Targeted Therapy.

[19]  Alexander Dömling,et al.  PROTACs– a game-changing technology , 2019, Expert opinion on drug discovery.

[20]  T. Lion,et al.  Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges , 2019, Journal of Hematology & Oncology.

[21]  Ziming Huang,et al.  Ubiquitin-specific peptidase 28 enhances STAT3 signaling and promotes cell growth in non-small-cell lung cancer , 2019, OncoTargets and therapy.

[22]  Y. Liu,et al.  USP28 contributes to the proliferation and metastasis of gastric cancer , 2018, Journal of cellular biochemistry.

[23]  Stephen P. Jackson,et al.  Deubiquitylating enzymes and drug discovery: emerging opportunities , 2017, Nature Reviews Drug Discovery.

[24]  Xinwei Han,et al.  miR-3940-5p Functions as a Tumor Suppressor in Non–Small Cell Lung Cancer Cells by Targeting Cyclin D1 and Ubiquitin Specific Peptidase-28 , 2016, Translational oncology.

[25]  Zengwu Wang,et al.  Ubiquitin-specific protease 28 is overexpressed in human glioblastomas and contributes to glioma tumorigenicity by regulating MYC expression , 2016, Experimental biology and medicine.

[26]  Biao Xu,et al.  Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth , 2015, Journal of cellular and molecular medicine.

[27]  R. Ankathil,et al.  BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. , 2014, Leukemia research.

[28]  Chi Wang,et al.  The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. , 2013, Cell reports.

[29]  K. Elenitoba-Johnson,et al.  Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. , 2009, The Journal of molecular diagnostics : JMD.